A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

The aim of this phase II trial was to estimate the objective response rate (ORR) of two different schedules of ixabepilone [weekly or every 3 weeks (Q3W)] combined with bevacizumab, relative to a reference arm of weekly paclitaxel and bevacizumab. Patients with human epidermal growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Campone, Mario, Amadori, Dino, Aldrighetti, Daniela, Conte, PierFranco, Wardley, Andrew, Villanueva, Cristian, Melisko, Michelle, McHenry, M. Brent, Liu, David, Lee, Francis, Pivot, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669514/
https://www.ncbi.nlm.nih.gov/pubmed/23649189
http://dx.doi.org/10.1007/s10549-013-2552-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669514/
https://www.ncbi.nlm.nih.gov/pubmed/23649189
http://dx.doi.org/10.1007/s10549-013-2552-8

Ejemplares similares